Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Change in Interest Receivables of -$6000.0 in Q4 2025, down 110.91% quarter-over-quarter from $55000.0 in Q3 2025, and up 89.29% on a YoY basis from -$3169.8 in Q4 2024.
Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Change in Interest Receivables history runs 5 years deep, the most recent figure standing at -$6000.0 for Q4 2025.
- In Q4 2025, Change in Interest Receivables rose 89.29% year-over-year to -$6000.0; the TTM figure through Dec 2025 stood at -$24000.0 (up 93.31% YoY), while the FY2025 annual figure was -$24000.0, up 93.31% from the prior year.
- Change in Interest Receivables was -$6000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $55000.0 in the prior quarter.
- In the past five years, Change in Interest Receivables ranged from a high of $609000.0 in Q2 2023 to a low of -$726000.0 in Q3 2023.
- Historically, Change in Interest Receivables has averaged -$52411.8 across 5 years, with a median of -$6000.0 in 2025.
- Biggest YoY gain for Change in Interest Receivables was 4975.0% in 2023; the steepest drop was 25400.0% in 2023.
- A 5-year view of Change in Interest Receivables shows it stood at $2000.0 in 2021, then sank by 27500.0% to -$548000.0 in 2022, then soared by 163.32% to $347000.0 in 2023, then tumbled by 116.14% to -$56000.0 in 2024, then soared by 89.29% to -$6000.0 in 2025.
- The last three Change in Interest Receivables figures came in at -$6000.0 (Q4 2025), $55000.0 (Q3 2025), and -$7000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -66,000.00 |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Jun 30, 2024 | -304,000.00 |
| Mar 31, 2024 | -117,000.00 |
| Dec 31, 2023 | 347,000.00 |
| Sep 30, 2023 | -726,000.00 |
| Jun 30, 2023 | 609,000.00 |
| Mar 31, 2023 | -253,000.00 |
| Dec 31, 2022 | -548,000.00 |
| Sep 30, 2022 | 48,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2021 | 2,000.00 |